Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis

Intrinsic odds look below 50%. This is a placebo-controlled Phase 2 study in moderate-to-severe ulcerative colitis using Week 8 clinical remission by modified Mayo, which is clinically meaningful but also a stringent efficacy bar. In this population, placebo-adjusted remission is difficult to achieve, and mid-stage UC programs generally need either strong prior signal, clear mechanistic differentiation, or enrollment enrichment to support better-than-average success odds. None of that supportive context appears in the provided fields, so the base case should stay conservative. The largest negative is operational: the trial is still listed as Not Yet Recruiting even though the estimated primary completion date has already passed. That mismatch creates real execution and disclosure risk, including delay, redesign, or failure to reach a clean readout. A stale registry is possible, so I would not push the probability extremely low, but on the facts given the combination of a tough endpoint, broad moderate-severe population, and major timeline inconsistency supports only a low-to-moderate chance of a positive result.

This trial faces compounding challenges. First, the study status remains 'Not Yet Recruiting' despite the estimated primary completion date having passed (Feb 2026), strongly suggesting major operational delays or potential cancellation. Second, CU104 is a novel barrier-function enhancer with only preclinical (mouse model) data published in Feb 2026; no human efficacy data exists. Third, the sponsor Curacle is a small Korean biotech with limited clinical execution track record. Fourth, the mechanism—targeting endothelial dysfunction and actin dynamics—is entirely unvalidated in human UC. Historically, Phase 2 UC induction trials for novel mechanisms succeed roughly 25-35% of the time, but given no Phase 1 UC data, a novel MOA, and severe execution risk (trial may never complete or produce results), the combined probability of positive results is substantially lower. The base rate for novel-mechanism Phase 2 success combined with operational non-completion risk yields an estimated ~18% probability of positive results.

This is a Phase 2 trial in ulcerative colitis with CU104, a drug with no prior clinical data provided. The trial status shows 'Not Yet Recruiting' despite the primary completion date having passed 33 days ago (daysToPrimaryCompletion: -33), indicating potential operational delays or abandonment. Phase 2 UC trials have moderate success rates but without any prior efficacy signals or safety data for CU104, the probability of positive results is below baseline. The endpoint (clinical remission at Week 8 via modified Mayo score) is standard and appropriate. Given the lack of prior data and concerning trial status, the intrinsic probability is estimated at 40%, slightly below even odds. The binary call is NO since probability is below 0.5, with confidence at the minimum 50 due to high uncertainty from limited trial information.

This Phase 2 trial in moderate-severe ulcerative colitis is still 'Not Yet Recruiting' as of the analysis date, with the primary completion date already past. This significant operational delay raises major disclosure and execution risks. The primary endpoint (clinical remission at Week 8) is standard but challenging in this population. The sponsor, Curacle Co., Ltd., is a smaller biotech, which can correlate with higher trial execution risk. Without any prior clinical data provided for CU104 in this indication, the intrinsic probability rests on the high bar of Phase 2 success and the current lack of patient enrollment. The combination of an unstarted trial and a passed completion date severely undermines confidence in a timely positive readout.

Phase 2 placebo-controlled trial of novel CU104 in moderate-severe UC uses standard primary endpoint: clinical remission (modified Mayo score 0-2) at Week 8, a high-quality, validated measure correlated with long-term outcomes. Patient population appropriately targets moderate-severe disease, enabling clear placebo comparison. No prior data on CU104 provided, consistent with early Phase 2; historical UC Phase 2 success rates ~20-25% for novel agents meeting primary statistical significance vs placebo. Sponsor Curacle (small Korean biotech) has execution history unknown but limited resources raise concerns. Critical flaw: 'Not Yet Recruiting' status as of 2026-04-02, with primary completion overdue by 33 days (est. 2026-02-28). This signals high operational risk—delayed recruitment likely cascades to enrollment shortfalls, data immaturity, or termination. Disclosure risk elevated if trial fails to complete. Derating base success to 18% accounts for execution uncertainty outweighing solid design.

The trial is a Phase 2 study of CU104, a novel drug, in ulcerative colitis. The primary endpoint of clinical remission at Week 8 is a standard and achievable goal in IBD trials. The placebo response in UC is typically 10-20%, while active drugs like JAK inhibitors achieve 30-40% remission. Assuming CU104 has a novel mechanism with promising preclinical data, a positive outcome is plausible. However, the status 'Not Yet Recruiting' and the sponsor being a smaller biotech introduces execution risk. I estimate a slightly better than even chance of success given the high unmet need and typical placebo rates, balanced against the risk of a novel MoA. I assign a 55% probability of success.

CU104 is a Phase 2 UC trial with a demanding primary endpoint: clinical remission at Week 8 using modified Mayo score 0-2. The trial is 'Not Yet Recruiting' despite an estimated primary completion date of February 2026 that has already passed (-33 days), indicating significant operational delays and possible enrollment challenges. Phase 2 IBD trials historically show high failure rates, with placebo remission rates in moderate-severe UC typically 10-15%. The sponsor Curacle is a smaller Korean biotech without established UC drug development track record. No prior Phase 1b data is disclosed in the summary to de-risk efficacy. The 8-week remission endpoint is stringent compared to symptomatic or endoscopic improvement alternatives. Disclosure risk is moderate—negative delays or protocol amendments could leak before formal readout.

Curacle voluntarily withdrew the Phase 2 IND for CU104 in moderate-to-severe ulcerative colitis on December 5, 2024. The sponsor explicitly stated a strategic decision to halt this pipeline program to consolidate operational execution and internal resources entirely on their lead asset, CU06. Consequently, trial NCT05907330 has been permanently abandoned before initiating patient enrollment. The study's estimated primary completion date of February 28, 2026, has already passed, yet the official clinical status remains 'Not Yet Recruiting' 33 days post-deadline. Without an active IND or enrolled patient population, generating primary endpoint data (clinical remission at Week 8) is impossible. Because the trial will yield no efficacy or safety data, it cannot report positive results. The probability of a YES resolution is effectively zero. The current market pricing of 48% YES reflects a profound information asymmetry, likely because the IND withdrawal was disclosed primarily through Korean regulatory channels and local press, leaving international prediction markets unaware of the program's termination.

The trial is in Phase 2, which has a relatively high failure rate. The primary endpoint is clinical remission at Week 8, which is a standard but challenging goal. Given that the study is not yet recruiting and has a long way to go before completion, there's considerable uncertainty. The sponsor, Curacle Co., Ltd., is a smaller company, which may add to the risk. However, the indication of ulcerative colitis and the intervention type suggest potential. Overall, these factors contribute to a cautiously low intrinsic probability of a positive result.